Nonoperating Income (Expense) of SELLAS Life Sciences Group, Inc. from 31 Dec 2010 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
SELLAS Life Sciences Group, Inc. quarterly and annual Nonoperating Income (Expense) in USD history and change rate from 31 Dec 2010 to 30 Sep 2025.
  • SELLAS Life Sciences Group, Inc. Nonoperating Income (Expense) for the quarter ending 30 Sep 2025 was $292,000, a 32% increase year-over-year.
  • SELLAS Life Sciences Group, Inc. Nonoperating Income (Expense) for the twelve months ending 30 Sep 2025 was $995,000, a 102% increase year-over-year.
  • SELLAS Life Sciences Group, Inc. annual Nonoperating Income (Expense) for 2024 was $632,000, a 19% increase from 2023.
  • SELLAS Life Sciences Group, Inc. annual Nonoperating Income (Expense) for 2023 was $529,000, a 18% decline from 2022.
  • SELLAS Life Sciences Group, Inc. annual Nonoperating Income (Expense) for 2022 was $649,000, a 85% decline from 2021.
Source SEC data
View on sec.gov
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Change (%)
Nonoperating Income (Expense), Annual (USD)
Nonoperating Income (Expense), YoY Annual Change (%)

SELLAS Life Sciences Group, Inc. Quarterly Nonoperating Income (Expense) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $995,000 $292,000 +$71,000 +32% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $924,000 $272,000 +$121,000 +80% 01 Apr 2025 30 Jun 2025 10-Q 12 Aug 2025 2025 Q2
Q1 2025 $803,000 $250,000 +$171,000 +216% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 $632,000 $181,000 +$140,000 +341% 01 Oct 2024 31 Dec 2024 10-K 20 Mar 2025 2024 FY
Q3 2024 $492,000 $221,000 +$127,000 +135% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025 2025 Q3
Q2 2024 $365,000 $151,000 -$59,000 -28% 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2025 2025 Q2
Q1 2024 $424,000 $79,000 -$105,000 -57% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q1
Q4 2023 $529,000 $41,000 01 Oct 2023 31 Dec 2023 10-K 20 Mar 2025 2024 FY
Q3 2023 $94,000 -$30,000 -24% 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2024 2024 Q3
Q2 2023 $210,000 +$1,000 +0.48% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024 2024 Q2
Q1 2023 $184,000 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q3 2022 $124,000 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $209,000 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q3 2019 $4,202,000 -$3,912,000 -1349% 01 Jul 2019 30 Sep 2019 10-Q 14 Nov 2019 2019 Q3
Q2 2019 $3,134,000 +$2,765,000 +47% 01 Apr 2019 30 Jun 2019 10-Q 14 Aug 2019 2019 Q2
Q3 2018 $290,000 +$4,102,000 +93% 01 Jul 2018 30 Sep 2018 10-Q 14 Nov 2019 2019 Q3
Q2 2018 $5,899,000 -$103,000 -1.8% 01 Apr 2018 30 Jun 2018 10-Q 14 Aug 2019 2019 Q2
Q3 2017 $4,392,000 01 Jul 2017 30 Sep 2017 10-Q 14 Nov 2018 2018 Q3
Q2 2017 $5,796,000 01 Apr 2017 30 Jun 2017 10-Q 14 Aug 2018 2018 Q2
Q4 2014 $15,616,000 $44,266,000 +$57,813,000 01 Oct 2014 31 Dec 2014 10-K 15 Mar 2017 2016 FY
Q3 2014 $42,197,000 $6,173,000 +$1,955,000 +24% 01 Jul 2014 30 Sep 2014 10-Q 05 Nov 2014 2014 Q3
Q2 2014 $44,152,000 $19,941,000 -$11,885,000 -148% 01 Apr 2014 30 Jun 2014 10-Q 11 Aug 2014 2014 Q2
Q1 2014 $32,267,000 $2,536,000 +$9,519,000 +79% 01 Jan 2014 31 Mar 2014 10-Q 06 May 2014 2014 Q1
Q4 2013 $41,786,000 $13,547,000 -$14,322,000 -1848% 01 Oct 2013 31 Dec 2013 10-K/A 15 Apr 2016 2015 FY
Q3 2013 $27,464,000 $8,128,000 -$7,395,000 -1009% 01 Jul 2013 30 Sep 2013 10-Q 05 Nov 2014 2014 Q3
Q2 2013 $20,069,000 $8,056,000 -$13,966,000 -236% 01 Apr 2013 30 Jun 2013 10-Q 11 Aug 2014 2014 Q2
Q1 2013 $6,103,000 $12,055,000 +$7,075,000 +37% 01 Jan 2013 31 Mar 2013 10-Q 06 May 2014 2014 Q1
Q4 2012 $13,178,000 $775,000 01 Oct 2012 31 Dec 2012 8-K 04 Dec 2015 2014 FY
Q3 2012 $733,000 01 Jul 2012 30 Sep 2012 10-Q/A 07 Nov 2013 2013 Q3
Q2 2012 $5,910,000 01 Apr 2012 30 Jun 2012 10-Q 09 Aug 2013 2013 Q2
Q1 2012 $19,130,000 01 Jan 2012 31 Mar 2012 10-Q 09 May 2013 2013 Q1

SELLAS Life Sciences Group, Inc. Annual Nonoperating Income (Expense) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $632,000 +$103,000 +19% 01 Jan 2024 31 Dec 2024 10-K 20 Mar 2025 2024 FY
2023 $529,000 -$120,000 -18% 01 Jan 2023 31 Dec 2023 10-K 20 Mar 2025 2024 FY
2022 $649,000 -$3,709,000 -85% 01 Jan 2022 31 Dec 2022 10-K 28 Mar 2024 2023 FY
2021 $4,358,000 +$4,150,000 +1995% 01 Jan 2021 31 Dec 2021 10-K 16 Mar 2023 2022 FY
2020 $208,000 +$19,581,000 01 Jan 2020 31 Dec 2020 10-K 31 Mar 2022 2021 FY
2019 $19,373,000 +$9,675,000 +33% 01 Jan 2019 31 Dec 2019 10-K 13 Mar 2020 2019 FY
2018 $29,048,000 -$5,547,000 -24% 01 Jan 2018 31 Dec 2018 10-K 13 Mar 2020 2019 FY
2017 $23,501,000 -$44,510,000 -212% 01 Jan 2017 31 Dec 2017 10-K 22 Mar 2019 2018 FY
2016 $21,009,000 +$25,380,000 01 Jan 2016 31 Dec 2016 10-K 15 Mar 2017 2016 FY
2015 $4,371,000 -$19,987,000 -128% 01 Jan 2015 31 Dec 2015 10-K 15 Mar 2017 2016 FY
2014 $15,616,000 +$57,402,000 01 Jan 2014 31 Dec 2014 10-K 15 Mar 2017 2016 FY
2013 $41,786,000 -$28,608,000 -217% 01 Jan 2013 31 Dec 2013 10-K/A 15 Apr 2016 2015 FY
2012 $13,178,000 -$22,257,000 -245% 01 Jan 2012 31 Dec 2012 8-K 04 Dec 2015 2014 FY
2011 $9,079,000 +$4,447,000 +96% 01 Jan 2011 31 Dec 2011 10-K 17 Mar 2014 2013 FY
2010 $4,632,000 01 Jan 2010 31 Dec 2010 10-K 28 Mar 2012 2011 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.